New Medical Treatment for Acromegaly

被引：5

作者：

Van Der Lely A.J. ^{[1
,2
]}

De Herder W.W. ^{[1
]}

Lamberts S.W. ^{[1
]}

机构：

[1] Department of Internal Medicine, Erasmus University

[2] Dept. of Medicine, University Hospital Dijkzigt, 3015 GD Rotterdam

来源：

Pituitary | 1999年 / 2卷 / 1期

关键词：

Acromegaly; Growth Hormone Receptor; Acromegalic Patient; Serum Prolactine Level; Dopaminergic Drug;

D O I：

10.1023/A:1009930223314

中图分类号：

学科分类号：

摘要：

The available somatostatin analogs for subcutaneous administration lower growth hormone (GH) levels in more than 90% of patients and Insulin-like growth factor-I (IGF-I) levels in up to 60%. They are also capable of reducing tumor size in up to 50%. Recently long-acting somatostatin analogs were introduced. The use of these application forms can result in normalization of IGF-1 in 60% of patients after 1 year and in 75% after 3 years. The development of selective analogs for the somatostatin receptor subtype-5 potentially will enhance the potency and the spectrum of the medical treatment of acromegaly with somatostatin analogs. The new generation of dopaminergic drugs also form a potentially effective and well tolerated therapy that should be considered in the management of those acromegalic patients, which have relative low serum IGF-I concentrations, along with high serum prolactine levels. Finally, growth hormone receptor (GHR) antagonists are under development for the use in humans. Preliminary results look promising, when biochemical parameters are concerned. Interim analysis of a phase 3 study with B2036-PEG in 38 patients does show that normalization of IGF-I concentrations is reached in at least 92% of the treated patients.

引用

页码：89 / 92

页数：3

共 38 条

[1]

Newman C.B., Melmed S., Snyder P.J., Et al., Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study, J Clin Endocrinol Metab, 80, pp. 2768-2775, (1995)

[2]

Lamberts S.W., Van Der Lely A.J., De Herder W.W., Hofland L.J., Octreotide, N Engl J Med, 334, pp. 246-254, (1996)

[3]

Melmed S., Acromegaly, Metabolism, 45, pp. 51-52, (1996)

[4]

Sheppard M.C., Stewart P.M., Treatment options for acromegaly, Metabolism, 45, pp. 63-64, (1996)

[5]

Tolis G., The role of somatostatin agonistic analogs in the treatment of acromegaly, Metabolism, 45, pp. 109-110, (1996)

[6]

Van Der Lely A.J., De H.W., Lamberts S.W., A risk-benefit assessment of octreotide in the treatment of acromegaly, Drug Saf, 17, pp. 317-324, (1997)

[7]

Vance M.L., Harris A.G., Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group, Arch Intern Med, 151, pp. 1573-1578, (1991)

[8]

Caron P., Morange-Ramos I., Cogne M., Jaquet P., Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide, J Clin Endocrinol Metab, 82, pp. 18-22, (1997)

[9]

Flogstad A.K., Halse J., Haldorsen T., Et al., Sandostatin LAR in acromegalic patients: A dose-range study, J Clin Endocrinol Metab, 80, pp. 3601-3607, (1995)

[10]

Marek J., Hana V., Krsek M., Et al., Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide, Eur J Endocrinol, 131, pp. 20-26, (1994)

← 1 2 3 4 →